SX-682 Recruiting Phase 1 Trials for Myelodysplastic Syndrome Treatment

Back to SX-682
IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT04245397
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome